153 related articles for article (PubMed ID: 33221151)
21. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
22. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
23. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
26. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
27. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
[TBL] [Abstract][Full Text] [Related]
28. Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Jamieson NB; Foulis AK; Oien KA; Dickson EJ; Imrie CW; Carter R; McKay CJ
J Gastrointest Surg; 2011 Mar; 15(3):512-24. PubMed ID: 21116727
[TBL] [Abstract][Full Text] [Related]
29. The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database.
Hu H; Xu Y; Zhang Q; Gao Y; Wu Z
Expert Rev Anticancer Ther; 2024 Jun; 24(6):467-476. PubMed ID: 38656796
[TBL] [Abstract][Full Text] [Related]
30. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.
Fukumoto T; Watanabe T; Hirai I; Kimura W
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):472-9. PubMed ID: 27246905
[TBL] [Abstract][Full Text] [Related]
32. Radiological prediction of portal vein infiltration in patients with pancreatic ductal adenocarcinoma.
Lapshyn H; Schulte T; Sondermann S; May K; Petrova E; Honselmann KC; Braun R; Zemskov S; Keck T; Wellner UF; Bausch D; Bolm L
Pancreatology; 2021 Jan; 21(1):155-162. PubMed ID: 33309623
[TBL] [Abstract][Full Text] [Related]
33. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
[TBL] [Abstract][Full Text] [Related]
34. Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma?
Clanton J; Oh S; Kaplan SJ; Johnson E; Ross A; Kozarek R; Alseidi A; Biehl T; Picozzi VJ; Helton WS; Coy D; Dorer R; Rocha FG
HPB (Oxford); 2018 Oct; 20(10):925-931. PubMed ID: 29753633
[TBL] [Abstract][Full Text] [Related]
35. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
36. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
37. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of preoperative [
Ding J; Qiu J; Hao Z; Huang H; Liu Q; Liu W; Ren C; Hacker M; Zhang T; Wu W; Huo L; Li X
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1780-1791. PubMed ID: 36695823
[TBL] [Abstract][Full Text] [Related]
39. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.
Chatterjee D; Rashid A; Wang H; Katz MH; Wolff RA; Varadhachary GR; Lee JE; Pisters PW; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Am J Surg Pathol; 2012 Apr; 36(4):552-9. PubMed ID: 22301496
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
